Angiotensin II exerts a mitogenic effect in several in vitro models, but a direct effect on erythroid progenitors has not been documented. Angiotensin-converting enzyme inhibitors and losartan, an angiotensin II type 1 receptor (AT 1 ) antagonist, ameliorate posttransplant erythrocytosis, without altering serum erythropoietin levels. We studied erythroid differentiation and the effect of angiotensin II on proliferation of erythroid progenitors by culturing CD34 ϩ hematopoietic progenitor cells in liquid serum-free medium favoring growth of erythroid precursors. Aliquots of cells were collected every third day, and were used for RNA preparation. AT 1 mRNA was detected after 6 d. In these same samples, erythroid-specific mRNA (erythropoietin receptor) was also detected. 
Introduction
Erythropoiesis is the dynamic process of red blood cell production. After erythroid commitment of undifferentiated pluripotent hematopoietic stem cells, subsequent cellular divisions amplify the early erythroid progenitors, providing the proper quantity of cells for terminal differentiation into mature erythrocytes. While the influences regulating commitment to the erythroid lineage are not fully understood, erythropoietin is an obligatory growth factor, increasing the number of progenitors by stimulating erythroid mitogenesis and differentiation, and by preventing apoptosis. A wide variety of factors, however, also stimulate erythropoiesis, including insulin-like growth factor 1 (IGF-1), granulocyte-macrophage colony stimulating factor (GM-CSF), IL-6, IL-1, activin-A, and basic fibroblast growth factor (1, 2) . Proliferation of the earliest primitive erythroid progenitors depends on growth factors not unique to erythropoiesis, of which IL-3 and stem cell factor may dominate (3, 4) . Additional influences may modulate erythroid proliferation by acting directly on erythroid progenitors, or indirectly through release of erythropoietic growth factors from nonerythroid cells.
Angiotensin II, which has a mitogenic effect on smooth muscle cells (5, 6) , may be one of these additional factors stimulating erythropoiesis, perhaps indirectly by increasing serum erythropoietin. Angiotensin-converting enzyme inhibitors decrease hematocrit in posttransplant erythrocytosis patients by mechanisms other than changes in circulating erythropoietin (7, 8) . Losartan, an angiotensin II type 1 receptor (AT 1 ) 1 -specific antagonist, decreases hematocrits in patients with posttransplant erythrocytosis (9, 10) .
To define how angiotensin II influences the red blood cell production, we studied expression of its receptor on erythroid progenitors and its effect on the in vitro proliferation of early erythroid progenitors. In addition, we studied early erythroid progenitors of posttransplant erythrocytosis patients, renal transplant recipients without erythrocytosis, and normal volunteers.
Methods
Early hematopoietic progenitor isolation and cell culture. Peripheral mononuclear cells from normal volunteers were isolated on a FicollHistopaque gradient (Sigma Chemical Co., St. Louis, MO). Undifferentiated early hematopoietic progenitors (CD34 ϩ cells) were labeled and separated using a CD34 ϩ cell magnetic sorting kit (Miltenyi Biotec Inc., Auburn, CA). The CD34 ϩ cell fraction was cultured for 15 d in StemPro-34SFM serum-free media (Life Technologies, Inc., Gaithersburg, MD) in the presence of 3 IU/ml erythropoietin, 20 ng/ml stem cell factor, and 20 ng/ml PIXY (a hybrid of IL-3 and GM-CSF), a Detection of AT 1 mRNA by reverse transcriptase PCR (RT-PCR). Aliquots of CD34 ϩ cells, cultured under conditions favoring erythroid differentiation (3 IU/ml erythropoietin, 20 ng/ml stem cell factor, and 20 ng/ml PIXY), were collected and stored. RNA was prepared using an RNeasy TM RNA isolation kit (QIAGEN Inc., Chatsworth, CA). After DNase treatment, synthesis of the corresponding cDNA was accomplished in one half aliquot of the cDNA using Superscipt II reverse transcriptase and DNase I (both purchased from Life Technologies, Inc.), according to manufacturer's recommendations. Because the full-length AT 1 coding sequence is in the last exon (exon 5) of the AT 1 gene (the other exons are alternatively spliced out), the AT 1 PCR amplifications were performed using RNA templates treated with reverse transcriptase (RT ϩ ) or without reverse transcriptase (RT Ϫ ). PCR amplification of the RT Ϫ templates served as a control for possible DNA contamination. The AT 1 sequence was amplified using outer primers AT 1 . Each cycle consisted of 1 min denaturation at 95 Њ C, 1 min annealing at 57 Њ C, and 2 min extension at 72 Њ C. Specificity of PCR amplification was confirmed by sequencing the subcloned PCR product. The same cDNA templates and PCR conditions as those for amplification of the mRNA for AT 1 were used for detecting mRNA for the erythropoietin receptor (EPOR), except for primers EPOR-1/2F: 5 Ј -caagttcgagagcaaagcggcct-3 Ј and EPOR-6/7R: 5 Ј -agagcccggcggtgggagagcag-3 Ј , and reverse nested primer EPOR-4/5R: 5 Ј -ctccaggatctccaccctctgta-3 Ј , and annealing at 60 Њ C. The quality of RNA preparation and cDNA synthesis was confirmed for all PCR templates by amplifying a ubiquitously expressed housekeeping gene, glucose-6-phosphate dehydrogenase (G6PD) (11) under the same conditions as those used for AT 1 amplification.
Western blotting of the burst-forming units-erythroid (BFU-E) colonies lysates.
Human bone marrow mononuclear cells were cultured in methylcellulose semisolid medium (MethoCult H-4531; Stem Cell Technologies, Vancouver, British Columbia) in 35-mm Petri dishes with 3 IU/ml of recombinant human erythropoietin (Life Technologies, Inc.). Cultures were maintained in a humidified atmosphere at 5% CO 2 , 21% O 2 at 37 Њ C. BFU-E colonies were scored at days 2, 7, and 14 using standard criteria (12, 13) . Individual BFU-E colonies were harvested from semisolid cultures at day 7, washed in 1 ϫ PBS, and lysed in lysis buffer containing 300 nM NaCl, 50 mM Tris HCl, pH 7.6, and 0.5% Triton X-100 (Sigma Chemical Co.), for 30-45 min on ice. After a 15-min centrifugation at 10,000 g , the supernatant containing solubilized membranes as well as cytosolic material was denatured for 5 min at 95 Њ C in 2 ϫ Laemmli buffer, and was separated by 10% SDS-PAGE (14) . The gel was electrophoretically transferred onto a 0.45-m nitrocellulose membrane (Schleicher and Schuell, Inc., Keene, NH) using semidry blotter (Bio-Rad Laboratories, Hercules, CA) (15) . The membrane was blocked with 5% nonfat milk in 1 ϫ PBS/0.05% Tween-20 overnight at 4 Њ C. Subsequent washing and dilutions were with 1 ϫ PBS/0.05% Tween-20 at room temperature. The primary rabbit anti-AT 1 polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) was detected by peroxidase-linked antirabbit antibody (Amersham Corp., Arlington Heights, IL). Activated chemiluminescence was detected on x ray film (Eastman Kodak Co., Rochester, NY) and was developed in a RP X-omat processor (Eastman Kodak Co.).
Stimulation of proliferation of early erythroid progenitors with angiotensin II in vitro and its inhibition by losartan, an AT 1 antagonist.
Early hematopoietic progenitors (CD34 ϩ cells) from normal volunteers were isolated and cultured in serum-free media with 3 IU/ml erythropoietin, 20 ng/ml stem cell factor, and 20 ng/ml PIXY, as described above. To evaluate a dose-dependent response of erythroid progenitors to angiotensin II, the cells were harvested on day 6 (a day on which earlier results had shown an appearance of AT 1 transcript), and were divided into aliquots. Aliquots containing 50,000 cells were cultured under the same conditions as before for three more days with various concentrations of angiotensin II (0, 1, and 100 nM, and 10 and 100 nM) added every 12 h. On day 9 the cells were washed with PBS, and were plated into methylcellulose semisolid media (MethoCult H4531) containing 0 or 3 IU/ml erythropoietin. The BFU-E colonies were scored 14 d after plating. To demonstrate that proliferation of erythroid progenitors was angiotensin II-specific, CD34 ϩ cells were cultured in serum-free Stem Pro-34SFM media with 3 IU/ml erythropoietin, 20 ng/ml stem cell factor, and 20 ng/ml PIXY for 9 d. Combinations of angiotensin II (0 and 100 nM) and losartan (0, 20, and 200 nM) were added every 12 h to the cultures on days 6-9. The BFU-E colonies were scored 14 d after plating.
Stimulation of proliferation of BFU-E-derived erythroid progenitors with angiotensin II.
Normal early hematopoietic progenitors (CD34 ϩ cells) were plated into MethoCult H4531-containing combinations of angiotensin II (0 and 100 M) and erythropoietin (0, 0.06, 0.125, 0.25, 0.5, 1, and 3 IU/ml). BFU-E colonies were scored 14 d after plating.
Detection of numbers of BFU-Es in renal transplant recipients.
Peripheral blood mononuclear cells were plated into MethoCult H431 containing erythropoietin (0, 0.03, 0.06, 0.125, 0.25, 0.5, 1, and 3 IU/ml). BFU-E colonies of four posttransplant patients with erythrocytosis and of eight renal transplant recipients without erythrocytosis were scored after 14 d. Each experiment was performed with identically handled peripheral blood mononuclear cells from normal individuals.
This study was approved by the Institutional Review Board for Human Use at the University of Alabama at Birmingham. Informed written consent was obtained from all subjects.
Results

Detection of mRNAs for AT 1 and erythropoietin receptor in cultures favoring differentiation to early erythroid progenitors.
Using nested RT-PCR with CD34 ϩ -derived progenitors, cells harvested at days 6, 9, and 12 had detectable AT 1 mRNA. This transcript was detected concomitantly with mRNA for the erythropoietin receptor (Fig. 1) . No mRNA for AT 1 or the erythropoietin receptor was detected on days 0-5. mRNA for G6PD was detected in every sample, confirming the adequacy of RNA and cDNA preparation, and served as a positive control in all cDNA samples.
Detection of AT 1 protein in BFU-E colonies. About 500 BFU-E colonies were individually harvested under direct vision with aid of an inverted microscope (16) , and were processed for Western blot analysis. These BFU-E colonies contained AT 1 protein, as detected by anti-AT 1 antibodies (Fig.  2) . Mononuclear leukocytes that constitutively express AT 1 (17) were used as a positive control. These data indicate that AT 1 is present on BFU-E-derived erythroid progenitors.
Angiotensin II augments erythropoiesis. Angiotensin II added to CD34 ϩ cultures on days six and nine increased the number of BFU-E colonies. A dose-dependent effect was observed when the angiotensin II concentration ranged from 10 nM-100 M (Fig. 3) . Losartan abolished this stimulatory effect of angiotensin II (Fig. 4) . Addition of angiotensin II before day 6 or after day 9 had only a minor or no discernible effect on the number of BFU-E colonies (data not shown). A possible direct effect of angiotensin II on the formation of BFU-E colonies was examined by adding angiotensin II to methylcellulose cultures containing different erythropoietin concentrations.
BFU-Es grown with or without angiotensin II showed no appreciable differences in colony size or morphology.
Angiotensin II does not cause formation of erythropoietinindependent BFU-E colonies. In the absence of erythropoietin, no BFU-E colonies were observed when plating the progenitors under optimal angiotensin II concentrations (see paragraph above). Thus, the stimulatory effect of angiotensin II did not substitute for that of erythropoietin in the development of BFU-E colonies.
Posttransplant erythrocytosis patients have increased numbers of erythroid progenitors in peripheral blood. Each posttransplant erythrocytosis patient was tested with identically handled normal control. No erythropoietin-independent BFU-E colonies were observed in posttransplant patients or in normal controls. The sensitivity of erythroid progenitors of posttrans- plant erythrocytosis patients in vitro to erythropoietin did not markedly differ compared to renal transplant recipients without erythrocytosis or normal volunteers (data not shown). The relative proportion of erythroid progenitors in renal transplant recipients with and without erythrocytosis is depicted in Fig. 5 .
Discussion
Our data support the hypothesis that angiotensin II stimulates erythropoiesis, and that this effect is mediated through its AT 1 receptor. The stimulatory effect of angiotensin II on erythropoiesis in vitro was observed only if the erythroid progenitors were cultured with erythropoietin, confirming the essential role of erythropoietin in erythropoiesis. Losartan (an AT 1 antagonist) added to cultures of early erythroid progenitors inhibited the stimulatory effect. Coupled with the finding that losartan lowers hematocrit in patients with posttransplant erythrocytosis (9, 10), we conclude that the AT 1 receptor signal transduction pathway plays a significant role in the pathogenesis of this clinically important complication.
A stimulatory effect of angiotensin II on erythropoiesis may be mediated by Jak-2 kinase. Binding of angiotensin to AT 1 receptors on smooth muscle cells activates this kinase (18) . Since AT 1 receptors are present on erythroid progenitors, angiotensin II may stimulate erythroid proliferation directly, and augment the effect of either the erythropoietin signal transduction pathway or that of other erythroid growth factors that share Jak-2 kinase-mediated signal transduction pathways. These growth factors, including IL-3, stem cell factor, IGF-1, GM-CSF, IL-6, and erythropoietin (19) (20) (21) (22) (23) , regulate erythropoiesis from the earliest erythroid progenitors to proerythroblasts. Our data suggest that angiotensin II likely increases proliferation of the earliest erythroid progenitors. Its effect on more committed progenitors was not pronounced because neither the number nor size of the colonies of more differentiated erythroid progenitors appreciably increased after angiotensin II stimulation.
Aberrant regulation in AT 1 receptor signal transduction pathway in posttransplant erythrocytosis patients is supported by our finding of increased proportion of erythroid progenitors in their peripheral blood as compared to normal controls, as well as to renal transplant recipients who did not develop erythrocytosis (Fig. 5) . 
